PMID- 35597922
OWN - NLM
STAT- MEDLINE
DCOM- 20220524
LR  - 20230916
IS  - 1471-2261 (Electronic)
IS  - 1471-2261 (Linking)
VI  - 22
IP  - 1
DP  - 2022 May 21
TI  - Recurrent heart failure hospitalizations increase the risk of mortality in heart 
      failure patients with atrial fibrillation and type 2 diabetes mellitus in the 
      United Kingdom: a retrospective analysis of Clinical Practice Research Datalink 
      database.
PG  - 234
LID - 10.1186/s12872-022-02665-y [doi]
LID - 234
AB  - BACKGROUND: Heart failure (HF) is a global illness and is a leading cause of 
      hospitalizations. Recurrent HF hospitalization (HFH) is associated with increased 
      risk of cardiovascular (CV) and all-cause mortality, thereby burdening the health 
      system. Type 2 diabetes mellitus (T2DM) and atrial fibrillation (AF) are two 
      important comorbidities in patients living with HF. This study aims to assess the 
      association between recurrent HFHs with CV and all-cause mortality in patients 
      living with HF and having AF and/or T2DM. METHODS: This study was conducted using 
      primary care data from the Clinical Practice Research Datalink database with 
      linkage to hospital data and mortality data. Adults living with HF and with at 
      least 1 HFH were identified from January 2010 to December 2014. Patients were 
      grouped based on the number of recurrent HFHs. During follow-up, all-cause 
      mortality or CV mortality for the HF population with AF and T2DM was recorded. 
      RESULTS: Overall, 32.9% of 2344 T2DM patients and 28.2% of 4585 AF patients had 
      at least 1 recurrent HFH. The patients were relatively elderly and were 
      predominantly male. The mean number of all-cause hospitalizations in HF patients 
      having T2DM and AF, with >/= 1 recurrent HFH were significantly higher than 
      patients without recurrent HFH. The annualized mortality rates in CV mortality as 
      the primary cause and for all-cause mortality and increased with recurrent HFHs, 
      in T2DM and AF patients. The risk of CV mortality as primary cause and all cause 
      morality were 5.39 and 3.19 times higher in T2DM patients with 3 recurrent HFHs 
      versus no recurrent HFH. Similarly, the risk of CV mortality as primary cause and 
      all cause morality was 5.98 and 4.3 times higher in AF patients with 3 recurrent 
      HFHs versus those with no recurrent HFH. CONCLUSIONS: Recurrent HFHs are strongly 
      associated with CV mortality and all-cause mortality in HF patients with TD2M or 
      AF. The hospitalization rate highlights the need for treatment and disease 
      management, which will improve the course of the disease and help patients stay 
      out of hospital.
CI  - (c) 2022. The Author(s).
FAU - Lahoz, Raquel
AU  - Lahoz R
AD  - Novartis Pharma AG, 4056, Basel, Switzerland.
FAU - Fagan, Ailis
AU  - Fagan A
AD  - Novartis Ireland Limited, 203 Merrion Rd, Dublin, D04 NN12, Ireland.
FAU - McSharry, Martin
AU  - McSharry M
AD  - Empower The User, Unit 1B, Trinity Technology & Enterprise Campus, Pearse St, 
      Dublin, D02 KD43, Ireland.
FAU - Proudfoot, Clare
AU  - Proudfoot C
AD  - Novartis Pharma AG, 4056, Basel, Switzerland.
FAU - Corda, Stefano
AU  - Corda S
AD  - Bayer AG, 51368, Leverkusen, Germany.
FAU - Studer, Rachel
AU  - Studer R
AD  - Novartis Pharma AG, 4056, Basel, Switzerland. rachel.studer@novartis.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220521
PL  - England
TA  - BMC Cardiovasc Disord
JT  - BMC cardiovascular disorders
JID - 100968539
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/complications/diagnosis/therapy
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Female
MH  - *Heart Failure/diagnosis/epidemiology/therapy
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Retrospective Studies
MH  - United Kingdom/epidemiology
PMC - PMC9124377
OTO - NOTNLM
OT  - Atrial fibrillation
OT  - Diabetes mellitus
OT  - Heart failure
OT  - Hospitalization
OT  - Mortality
COIS- RL, RS and CP are employees of Novartis Pharma AG and holds shares of Novartis 
      Pharma AG. AF is an employee of Novartis Ireland Limited, Dublin. MMS was an 
      employee of Novartis Ireland Limited, Dublin when this study was conducted and is 
      currently an employee of Empower The User, Dublin. SC was an employee of Novartis 
      Pharma AG when this study was conducted and is currently an employee of Bayer.
EDAT- 2022/05/22 06:00
MHDA- 2022/05/25 06:00
PMCR- 2022/05/21
CRDT- 2022/05/21 23:34
PHST- 2021/09/16 00:00 [received]
PHST- 2022/04/07 00:00 [accepted]
PHST- 2022/05/21 23:34 [entrez]
PHST- 2022/05/22 06:00 [pubmed]
PHST- 2022/05/25 06:00 [medline]
PHST- 2022/05/21 00:00 [pmc-release]
AID - 10.1186/s12872-022-02665-y [pii]
AID - 2665 [pii]
AID - 10.1186/s12872-022-02665-y [doi]
PST - epublish
SO  - BMC Cardiovasc Disord. 2022 May 21;22(1):234. doi: 10.1186/s12872-022-02665-y.